Robert Driscoll Analyst PerformanceSenior Vice President, Equity Research at WedbushRobert Driscoll is a stock analyst at Wedbush, covering 15 publicly traded companies across a range of sectors. Over the past year, Robert Driscoll has issued 12 stock ratings, including buy and hold recommendations. While full access to Robert Driscoll's proprietary MarketBeat Analyst Rating is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Robert Driscoll's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Ratings, Coverage, and Performance StatisticsAnalyst RatingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings20 Last 7 YearsBuy Recommendations70.00% 14 Buy RatingsCompanies Covered15 Unique Companies Ratings Distribution20RatingsDistribution of strong buy, buy, hold, and sell ratings by Robert Driscoll.RatingPercentageCount Strong Buy0.0%0 ratings Buy70.0%14 ratings Hold25.0%5 ratings Sell5.0%1 ratingsOut of 20 total stock ratings issued by Robert Driscoll at Wedbush, the majority (70.0%) have been Buy recommendations, followed by 25.0% Hold and 5.0% Sell.Best & Worst CallsBest Call000.0%KURASep 2019Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%AKAOFeb 2018Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ100.0% of companies on NASDAQ15 companiesRobert Driscoll, an analyst at Wedbush, currently covers 15 companies listed on , with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical15 companies100.0%Robert Driscoll of Wedbush specializes in stock coverage within the Medical sector.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE10 companies66.7%BIOTECHNOLOGY2 companies13.3%PHARMACEUTICAL PREPARATIONS2 companies13.3%MED - DRUGS1 company6.7% About Robert DriscollRobert Driscoll, Ph.D., has over a decade in research and analytics in the life sciences sector – specifically in the area of oncology and more recently in the areas of infectious disease. He is a molecular biologist who received his Ph.D. from the University of Cambridge, and spent six additional years working in the lab at Stanford. He is particularly interested in the development and causes of cancer, as well as the expanding world of immuno-oncology. Since joining Wedbush in 2014, Robert has been covering a number of cutting-edge companies that include Arvinas (ARVN), Kura Oncology (KURA), Arcus Biosciences (RCUS), and IGM Biosciences (IGMS). Robert received his Bachelor’s degree in Biochemistry from the University of Leeds, and his Ph.D. in Cellular and Molecular Biology from the University of Cambridge. He also completed a postdoctoral fellowship at Stanford University.Follow on LinkedIn Robert Driscoll's Ratings History at Wedbush Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Time Frame Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export to Excel CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsREPLReplimune Group7/22/2025Reiterated Rating$3.14$4.00Neutral$0.0000.00% ROICBIOCrescent Biopharma7/14/2025Initiated Coverage$12.96$27.00Outperform$0.0000.00% ROIKURAKura Oncology6/20/2025Reiterated Rating$6.06$36.00Outperform$0.0000.00% ROIZNTLZentalis Pharmaceuticals5/15/2025Reiterated Rating$1.18$4.00Neutral$0.0000.00% ROIHOWLWerewolf Therapeutics5/9/2025Lower Price Target$0.82$6.00Outperform$0.0000.00% ROIRVMDRevolution Medicines4/28/2025Reiterated Rating$41.02$67.00Outperform$0.0000.00% ROIZNTLZentalis Pharmaceuticals3/28/2025Reiterated Rating$1.70$4.00Neutral$0.0000.00% ROIGLUEMonte Rosa Therapeutics3/20/2025Reiterated Rating$7.06$17.00Outperform$0.0000.00% ROIARVNArvinas3/12/2025Downgrade$8.30$12.00Neutral$0.0000.00% ROIHOWLWerewolf Therapeutics3/12/2025Reiterated Rating$1.30$8.00Outperform$0.0000.00% ROIDAWNDay One Biopharmaceuticals2/26/2025Reiterated Rating$10.25$32.00Outperform$0.0000.00% ROIKURAKura Oncology2/6/2025Boost Price Target$8.13$36.00Outperform$0.0000.00% ROI Stock Forecasts and Research Tools Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.